CPB2

Across TCGA pan-cancer cohorts, CPB2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CPB2 data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CPB2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CPB2 expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

HNSC, SKCM, and UCEC are the cancer types where CPB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.138	0.674	.015	12	view →
SKCM	DFS	Median	All	0.063	0.757	.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	DFS	Median	All	0.097	0.543	.033	6	view →
SCLC	DFS	Median	III,IV	1.000	0.211	.023	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CPB2–HNSC (OS)

Open the HNSC breakdown →